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Summary
The adhesion of infected red blood cells (iRBCs) to
human endothelium is considered a key event in
the pathogenesis of cerebral malaria and other life-
threatening complications caused by the most
prevalent malaria parasite Plasmodium falciparum.
In the past 30 years, 14 endothelial receptors for
iRBCs have been identified. Exposing 10 additional
surface proteins of endothelial cells to a mixture of
P. falciparum isolates from three Ghanaian malaria
patients, we identified seven new iRBC receptors,
all expressed in brain vessels. This finding
strongly suggests that endothelial binding of
P. falciparum iRBCs is promiscuous and may use a
combination of endothelial surface moieties.
Introduction
Severe malaria caused by infection with Plasmodium
falciparum is a complex clinical syndrome comprising a
number of life-threatening conditions including cerebral
malaria (CM). Several lines of evidence indicate that a
major mechanism underlying the pathology of CM is the
‘cytoadherence’ of infected red blood cells (iRBCs) to the
endothelium lining the microvasculature of the brain,
which may cause disturbances of the cerebral blood flow
and metabolism as well as local inflammatory responses
(Berendt et al., 1994; van der Heyde et al., 2006).
Cytoadherence is mediated by the binding of
Plasmodium-derived proteins exposed on the surface
of iRBCs to defined structures on endothelial cells. One
of the major adhesion molecules of the parasite is the
P. falciparum erythrocyte membrane protein 1 (PfEMP1)
(Leech et al., 1984). PfEMP1 comprises a great variety
of proteins encoded by 60 var genes in the individual
parasite genome and numerous variants in the parasite
population at large. By varying and switching var gene
expression the parasites show different and changing
binding phenotypes, accompanied by antigenic variation
(Miller et al., 2002).
Until now, 14 endothelial surface structures have been
identified to serve as receptors for P. falciparum iRBCs,
including CD36, intercellular adhesion molecule-1 (ICAM-
1), vascular cell adhesion molecule-1 (VCAM-1), platelet/
endothelial cell adhesion molecule (PECAM-1), neural
cell adhesion molecule (NCAM) and endothelial protein C
receptor (EPCR). Additionally, chondroitin sulfate A (CSA)
expressed on syncytiotrophoblast cells can serve as
attachment points for iRBCs in the placenta. Only CD36,
ICAM-1, PECAM-1, EPCR and CSA have been studied in
detail (Serghides et al., 2003; Chakravorty and Craig,
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cellular microbiology
2005; Rowe et al., 2009; Berger et al., 2013; Moxon et al.,
2013; Turner et al., 2013), revealing a unique associa-
tion of binding to CSA with placental malaria (Duffy
and Fried, 2005). For CM it remains unclear whether
any single one of the known endothelial structures
has a pivotal role. ICAM-1 was implicated by immun-
opathological studies of post-mortem tissues showing
colocalization of sequestration with ICAM-1 expression in
the brain (Turner et al., 1994) and by an in vitro analysis of
isolates from CM patients preferentially binding to recom-
binant ICAM-1 (Newbold et al., 1997). In studies with field
isolates from Asia, however, ICAM-1 binding was not
associated with severe malaria (Ockenhouse et al., 1991;
Udomsangpetch et al., 1996). CD36 is the quantitatively
most important receptor as almost all non-placental
P. falciparum isolates derived from patients bind to it, but
a major role of CD36 in cerebral malaria is uncertain
because (i) the degree of binding to CD36 by iRBCs
isolated from malaria patients did not correlate with sever-
ity of the disease (Newbold et al., 1997) and (ii) CD36
expression levels on brain endothelial cells was found to
be low in CM patients (Turner et al., 1994). EPCR is the
most recently identified endothelial receptor, which has
been implicated in the pathology of severe malaria. While
Turner et al. showed the direct interaction of EPCR with
domain cassettes 8 and 13 of PfEMP1 (Turner et al.,
2013), Moxon and colleagues revealed a role of EPCR in
CM using an entirely different approach (Moxon et al.,
2013). In post-mortem studies of children who died of CM,
they observed a colocalization of endothelial sites of
adherent iRBCs and a loss of EPCR antigens.
For a better understanding of the pathology of CM but
also for strategies to develop a vaccine against CM, it is of
relevance whether the repertoire of endothelial receptors
for iRBC is rather limited or broader than presently rec-
ognized. Therefore, we studied 10 surface moieties of the
cerebral endothelium for their ability to serve as iRBC
receptors. Seven of these showed iRBC binding when a
mixture of patient isolates of P. falciparum from Ghana,
West Africa, was used. This finding strongly suggests that,
in contrast to our present understanding, endothelial
binding of P. falciparum iRBC is highly promiscuous.
Results and discussion
The tetraspanins CD9 and CD151, multidrug-resistance
protein 1 (MDR1), multidrug resistance-associated protein
2 (MRP2), the histamine H1 receptor (HRH1), oxidized
low-density lipoprotein receptor 1 (LOX1) and vascular
adhesion protein 1 (VAP-1) as well as truncated forms
of tumour necrosis factor receptors 1 (TNFR1) and 2
(TNFR2) and the erythropoietin receptor (EPOR) were
expressed in glycosaminoglycan-deficient Chinese ham-
ster ovary (CHO-745) cells. All have been shown to be
expressed on human brain endothelial cells (Cordon-
Cardo et al., 1989; Rossler et al., 1992; Salmi et al., 1993;
Purkiss et al., 1994; Sawamura et al., 1997; Sincock
et al., 1997; Dombrowski et al., 2001; Kadhim et al., 2006;
Wosik et al., 2007; Medana et al., 2009). Tagged with
green fluorescent protein (GFP) at their intracellular
domains, the proteins were localized to the cell mem-
brane by microscopy, and extracellular exposure was con-
firmed using non-permeabilized cells probed with specific
antibodies; exceptions were LOX1, which was not GFP
labelled but shown to be surface expressed by antibody
staining, and MRP2, for which no antibodies or antisera
are available directed to extracellular domains but which
showed a characteristic GFP fluorescence at the outer
cell membrane (Fig. S1). Binding of P. falciparum iRBCs
was studied using trophozoite stages of the laboratory
strain FCR3 and of isolates from three Ghanaian patients
with severe falciparum malaria. The patients’ samples
were pooled, expanded, frozen in aliquots and used as
such in order not to introduce additional artefacts by
cloning and prolonged in vitro cultivation. Cells trans-
fected with CD36, which has been found to bind iRBC
from almost all P. falciparum isolates (Newbold et al.,
1997; Rowe et al., 2009), were used as positive controls
for adhesion.
Significant binding of the pool of field isolates to CHO-
745 cells transfected with CD9, CD151, MDR1, MRP2, or
truncated forms of EPOR (EPORsh), TNFR1 (TNFR1sh)
and TNFR2 (TNFR2sh) was detected (Fig. 1A) whereas
the laboratory strain FCR3 showed marginal binding, if
any (Fig. 1B). Neither FCR3 nor the field isolates caused
iRBC binding to cells transfected with HRH1, LOX1 or
VAP-1 (Fig. 1A and B) while both bound most strongly to
the positive control CD36. Inhibition assays were per-
formed with purified immunoglobulin G from rat or rabbit
antisera (αCD9, αCD151, αEPOR, αTNFR1) and mouse
monoclonal antibodies (αMDR1, αTNFR2) respectively.
All showed statistically significant inhibition in a dose-
dependent manner, confirming the specificity of the
binding reactions of MDR1, EPOR, TNFR1 and TNFR2
(Fig. 2). This interpretation is less straightforward for
the tetraspanins CD9 and CD151 because their major
function is to assemble multi-component complexes
on cellular surfaces, so-called tetraspanin-enriched
microdomains, which may enhance the binding capacity
of other cellular receptors (Barreiro et al., 2005). These
might include NCAM and other, as yet uncharacterized
iRBC receptors which may be present on non-transfected
CHO-745 cells (Andrews et al., 2005; Pouvelle et al.,
2007).
We conclude from our data that the binding behaviour
of P. falciparum iRBCs is highly promiscuous. If our find-
ings obtained with a field isolate pool can be extrapolated
to the plethora of parasite clones in the field, it would
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suggest that P. falciparum may take advantage of many
endothelial surface moieties for the adhesion of iRBCs. As
indicated by the binding to MDR1 and MRP2, this may
include structures which physiologically do not function as
cellular receptors, as has first been noted for chondroitin
sulfate A (Rogerson et al., 1995). Possibly the knob-like
protrusions formed by the parasite at the iRBC surface
allow binding to surface structures that are less prominent
than genuine receptors.
Certain lines of evidence have indicated that ICAM-1
and EPCR may play a pivotal role in the adhesion of iRBC
in cerebral vessels and, therefore, in the pathology of CM
(Turner et al., 1994; 2013; Newbold et al., 1997; Moxon
et al., 2013). Our data indicate, however, that multiple
‘receptors’ may participate in the binding of iRBCs to
cerebral endothelia as all seven iRBC receptors identified
here have been shown to be expressed on endothelial
cells of the human brain (Cordon-Cardo et al., 1989;
Rossler et al., 1992; Sincock et al., 1997; Dombrowski
et al., 2001; Kadhim et al., 2006; Wosik et al., 2007;
Medana et al., 2009). In fact, it is conceivable that the
brain may be a common site of iRBC adhesion and
sequestration because, constituting the blood–brain
barrier, the cerebral endothelium is extraordinarily rich
in receptor and transporter molecules offering a broad
variety of binding sites for iRBCs, which all in all are
armed with an even broader variety of adhesion ligands
(Miller et al., 2002). Thus, our findings could question
present concepts of developing anti-disease vaccines in
malaria based on the inhibition of cerebral iRBC adhesion
(Smith et al., 2000).
Except for the adhesion itself, functional implications of
the newly discovered binding reactions have not been the
objective of our study and, to this end, any considerations
must remain highly speculative. Nevertheless, some com-
ments appear justified.
Several mechanisms have been proposed of how
endothelial adhesion of P. falciparum iRBC might contrib-
ute to organ failure and, in particular, to CM. One is the
concept of a mechanical occlusion of blood flow by a
‘sludge’ of adherent iRBCs, which bind additional iRBCs
as well as uninfected RBCs and platelets. More recently,
it has been discussed that microcirculatory disturbances
could also be initiated by pro-inflammatory cytokines,
which are released systemically or locally through adher-
ent iRBCs (Clark et al., 2006). These and additional
mechanisms might involve the deregulation of endothelial
receptor signalling and the damaging of endothelial
barrier functions by iRBCs (Miller et al., 2002). Therefore,
an elucidation of the role of the adhesion process in the
development of severe malaria requires further studies.
CD9 and CD151 belong to the protein family of
tetraspanins, which have been found to be involved in a
variety of cellular functions including proliferation, adhe-
sion, migration, cell fusion as well as binding and process-
ing of pathogens. They may contribute to the cellular
attachment of certain bacteria (Green et al., 2011)
and have been shown to be utilized by P. falciparum
sporozoites (Silvie et al., 2003) and several viruses for
host cell entry (Pileri et al., 1998; Yoshida et al., 2008).
A physical association of CD9 and CD151 with ICAM-1
and VCAM-1 has been reported to play a crucial role in
the firm adhesion of leucocytes during extravasation
(Barreiro et al., 2005). Both ICAM-1 and VCAM-1 are
well-known iRBC receptors (Rowe et al., 2009). There-
fore, direct binding of iRBCs to the tetraspanins may
Fig. 1. Binding of P. falciparum iRBCs to endothelial surface proteins expressed on CHO cells. Binding of RBCs infected with a pool of
P. falciparum isolates from Ghanaian patients (A) or P. falciparum laboratory strain FCR3 (B) to CHO-745 cells expressing CD36, CD9,
CD151, MDR1, EPORsh, TNFR1sh, TNFR2sh, MRP2, HRH1, LOX1 and VAP-1 respectively. Bars indicate median iRBC numbers specifically
bound to 100 CHO cells as determined by microscopic inspection of 500 CHO cells in three independent experiments, each performed in
triplicate.
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Fig. 2. Inhibition of P. falciparum iRBC binding by antibodies to endothelial surface proteins. Inhibition of iRBC binding infected with a mixture
of P. falciparum patient isolates to CHO cells expressing the endothelial surface proteins CD9 (A), CD151 (B), MDR1 (C), EPORsh (D),
TNFR1sh (E) and TNFR2sh (F) by antibodies to endothelial surface proteins as indicated. Binding to cells expressing CD36 (CD36) and
binding inhibition by non-specific mouse IgG2a (IgG) were used for control. Binding in the presence of 10 μg ml−1 (10) and 100 μg ml−1 (100)
antibodies is compared to the binding in the absence of antibodies (−). Median percentages with ranges of three independent experiments are
shown, each performed in triplicate. Asterisks mark significant differences with P < 0.05.
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further contribute to a deregulation of leucocyte traffick-
ing, which may play an important role in the pathogenesis
of CM (Miller et al., 2002). Furthermore, CD9 is expressed
on platelets (Miao et al., 2001), and clumping of iRBCs
and platelets has been found associated with CM (Pain
et al., 2001). Thus, similar to CD36, CD9 may contribute
to the clumping of iRBCs and platelets and to the binding
of such aggregates to the vessel wall.
Cerebral sequestration of iRBCs has been found to be
positively correlated with the expression of EPOR in brain
vessels (Medana et al., 2009), which is in good agree-
ment with our finding of iRBC binding to EPOR. While
the function of EPOR on brain endothelial cells is not yet
fully understood, it has been reported that EPOR acts
as an active transporter of erythropoietin (EPO) across
the blood–brain barrier (Brines et al., 2000) and that
EPO inhibits the permeability of the blood–brain barrier
(Casals-Pascual et al., 2008). In addition, elevated EPO
concentrations in the plasma of children with CM have
been found associated with a reduced risk of neurological
sequelae (Martinez-Estrada et al., 2003). Therefore, EPO
is being discussed as a neuroprotective agent and an
adjuvant treatment for severe malaria. Thus, binding of
iRBCs to EPOR might contribute to the pathology of CM
not only by disturbing the cerebral microcirculation but
also by affecting the integrity of the blood brain barrier
through blocking of EPO binding sites.
Several lines of evidence indicate that TNF plays an
important role in the development of CM (Grau et al.,
1989; Kwiatkowski et al., 1990), and its two receptors
TNFR1 and TNFR2 are most likely to mediate this
effect. It is reasonable to assume that direct binding
of iRBCs to these receptors could in one way or
another modify TNF activities, including the induction
and upregulation of ICAM-1 and other endothelial iRBC
receptors (Mackay et al., 1993; Lucas et al., 1997;
Stoelcker et al., 2002).
MDR1 and MRP2 are ATP-Binding-Cassette (ABC)
transporters that may play a critical role in neuro-
protection by eliminating a wide range of toxic com-
pounds from the brain (Begley, 2004). Both proteins span
the cell membrane multiple times with their functional
ATP-binding cassettes located at the cytosolic side.
Neither transporter has so far been recognized to serve
as receptors nor have they been implicated in the attach-
ment or invasion of pathogens. Therefore, our data on
MDR1 and MRP2 show that P. falciparum iRBC may use
an extraordinarily broad variety of endothelial surface
structures for adherence.
In conclusion, it is conceivable that the additional
endothelial receptors for iRBC described here may con-
tribute to the pathology of severe malaria and, in particu-
lar, of CM through a number of mechanisms, which,
besides the mechanical obstruction of blood flow, possibly




Patient isolates were collected from three children diagnosed
with severe falciparum malaria of a case–control study conducted
in Kumasi, Ghana (May et al., 2007). The study had been
approved by the Committee for Research, Publications and
Ethics of the School of Medical Sciences, Kwame Nkrumah Uni-
versity of Science and Technology, Kumasi, Ghana (reference
number CHRPE/01/11). All procedures were explained to parents
or guardians of the participating children in the local language,
and written or thumb-printed informed consent was obtained
(May et al., 2007).
Animal use for antisera generation was carried out in
strict accordance with the recommendations of the European
Union guidelines for the handling of laboratory animals
(Directive 2010/63/EU of the European Parliament and the
Council of 22 September 2010 on the protection of animals
used for scientific purposes). The procedures were approved by
the Behörde für Gesundheit und Verbraucherschutz der Stadt
Hamburg according to §10a TierSchG (German Protection of
Animals Act).
P. falciparum isolates
Plasmodium falciparum strain FCR3 was obtained from Dr
Mo-Quen Klinkert. In vitro cultivation of P. falciparum was carried
out in human Rh-positive RBCs of blood group 0 according to
standard protocols (Trager and Jensen, 1976). Patient isolates
were cryopreserved, adapted to in vitro cultivation and pooled.
Parasite growth was synchronized using 5% sorbitol (Lambros
and Vanderberg, 1979).
Protein expression by CHO cells
Chinese hamster ovary cells defective in glycosaminoglycan
biosynthesis (CHO-745) were obtained from American Type
Culture Collection (Esko et al., 1985) and grown in Ham’s F-12
media (PAA Laboratories) supplemented with 10% fetal calf
serum, penicillin and streptomycin. Expression constructs were
generated according to established protocols. cDNA of CD9 and
CD151 were cloned into pEGFP-N1 (Clontech Laboratories),
MDR1, MRP2 and HRH1 (Missouri S&T cDNA Resource Center)
into pAcGFP-N1 (Clontech Laboratories), and cDNA of VAP-1
and LOX1 (ImaGenes GmbH) into pAcGFP-C1 (Clontech Labo-
ratories) and pcDNA3.1(+) (Invitrogen) respectively. For EPOR,
TNFR1 and TNFR2 (ImaGenes GmbH) intracellularly truncated
forms (EPORsh, TNFR1sh and TNFR2sh respectively) were
generated by cloning amino acids 1–336 of EPOR (using primers
1 and 2), amino acids 1–252 of TNFR1 (using primers 3 and 4)
and amino acids 1–307 of TNFR2 (using primers 5 and 6) into
pAcGFP-N1.
Primer 1: 5′-AAT AAG CTT ACC ACC ATG GAC CAC CTC GGG
GCG-3′
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Primer 2: 5′-ATT CCG CGG TGA CTC TGA GAG GAC TTC
CAG-3′
Primer 3: 5′-AAT CTC GAG ACC ACC ATG GGC CTC TCC ACC
GTG-3′
Primer 4: 5′-CAA TCC GCG GTG TCG ATT TCC CAC A-3′
Primer 5: 5′-AAT CTC GAG ACC ACC ATG GCG CCC GTC GCC
GTC-3′
Primer 6: 5′-CAA TCC GCG GCT TAT CGG CAG GCA A-3′
CHO-745 cells were transfected using Lipofectamine 2000
(Invitrogen) complexed with pAcGFP1-N1, pEGFP-CD9, pEGFP-
CD151, pAcGFP-MDR1, pAcGFP-EPORsh, pAcGFP-TNFR1sh,
pAcGFP-TNFR2sh, pAcGFP-MRP2, pAcGFP-HRH1, pcDNA3.1-
LOX1 and pAcGFP-VAP-1, respectively, according to the proto-
col of the manufacturer. Two days after transfection, 0.7 mg ml−1
G418 (Biochrom AG) was added to the cultures. G418-resistant
cells were harvested and subjected to FACS sorting using a BD
FACSAria cell sorter (BD Biosciences). Single-cell clones were
maintained in 96-well plates and screened for plasma membrane
expression of recombinant proteins.
Antibodies
The following antibodies were used for immunofluorescence and
inhibition studies: Mouse αMDR1 (UIC2, Millipore), αTNFR2
(MAB226, R&D Systems), αHRH1 (MAB4726, R&D Systems),
αVAP-1 (TK8-14, Santa-Cruz) and purified mouse IgG2a
(MOPC-173, Biozol) were purchased. Immune sera against
human CD9, CD151, EPOR, TNFR1 and LOX1 were generated
by cDNA immunization. Full-length cDNA fragments of CD9,
CD151 and LOX1 and truncated forms of EPOR (EPORsh) and
TNFR1 (TNFR1sh) were cloned into pcDNA3.1(+) vector
(Invitrogen) and coated onto 1 μm-gold particles (Bio-Rad).
cDNA of CD9, EPORsh and TNFR1sh was ballistically injected
into rats and cDNA of CD151 and LOX1 into rabbits at a pressure
setting of 400 psi. Gene gun immunization was repeated three
times at 6-week intervals (Koch-Nolte et al., 2005). The immune
sera were tested by immunofluorescence staining of CHO cells
transfected with CD9, CD151, EPORsh, TNFR1sh and LOX1
respectively. IgG-antibodies were purified from sera by Protein G
Sepharose 4 Fast Flow according to the protocol of the manu-
facturer (GE Healthcare) and referred to as αCD9, αCD151,
αEPOR, αTNFR1 and αLOX1.
Immunofluorescence studies
CHO-745 cells were grown on coverslips and fixed with 4%
para-formaldehyde. Surface-exposed CD9, CD151, MDR1,
EPORsh, TNFR1sh, TNFR2sh, HRH1, LOX1 and VAP-1 were
labelled using the respective antibodies and secondary antibod-
ies conjugated to Alexa-Fluor-594 (Invitrogen). Nuclei were
stained with DAPI at 0.1 μg ml−1 (Sigma). Fluorescence-labelled
cells were inspected using a Zeiss Axioskop2 plus microscope
(Carl Zeiss AG). Mock-transfected cells did not react with any of
the specific antisera, and CHO cells transfected with endothelial
receptors incubated with pre-immune sera or with secondary
antibodies alone did not show fluorescence in any experiment.
Static iRBC adhesion assays
Stably transfected CHO-745 cells were grown on 13 mm
coverslips and maintained in 24-well plates. CHO-745 cells were
seeded at a density of 15 000 cells per well and grown for 48 h
before assays. For inhibition assays, CHO-745 transfectants
were pre-incubated with antibodies at 37°C for 30 min.
Trophozoite stage parasite cultures at 1% haematocrit and 4%
parasitaemia in binding medium (RMPI medium 1640 supple-
mented with 2% glucose, pH 7.2) were applied to CHO-745
transfectants and incubated at 37°C for 1 h with gentle mixing at
10 min intervals. Afterwards, unbound erythrocytes were gently
removed by washing with binding medium, and the cells were
fixed with 1% glutaraldehyde in PBS at room temperature for 1 h.
Cells on coverslips were stained with Giemsa, and the numbers
of adherent iRBCs per 500 CHO-745 cells were counted using a
light microscope. Assays were performed in triplicate in three
independent experiments, in each case determining the binding
of iRBCs to mock-transfected CHO-745 and CHO-745-CD36 for
reference. The numbers of iRBCs bound to mock transfectants
were subtracted from the numbers of iRBCs bound to CHO-745
cells expressing recombinant proteins. If this resulted in a nega-
tive value, the number of specifically bound iRBCs was set to
zero. On average, 25.9 ± 34.9 iRBCs bound to 100 mock-
transfected CHO-745 cells, which could not be inhibited by
adding any of the antibodies to the endothelial surface proteins
studied. Data are presented as median with range. For inhibition
assays, binding in the presence of antibodies was expressed as
percentage of binding in the absence of antibodies. For statistical
evaluations the non-parametric Mann–Whitney U test was used,
whereby two-sided P-values of < 0.05 were considered signifi-
cant (n = 6).
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Supporting information
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Fig. S1. Antibody staining of recombinant proteins expressed on
the surface of CHO-745 cells. Immunofluorescence analyses
(IFA) with non-permeabilized CHO-745 cells confirm surface
localization of the overexpressed endothelial proteins. GFP-
tagged CD9, CD151, MDR1, EPORsh, TNFR1sh, TNFR2sh,
HRH1, VAP-1 (green) as well as untagged LOX1 expressed in
CHO-745 cells were labelled with respective antibodies (red). No
antibodies were available which are directed against any of the
nine extracellular domains of MRP2. Nuclei were stained with
DAPI (blue). n.d., not determined.
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